Where Are We Going? Future Perspectives on Navigating the Treatment Paradigm in Transplant-Eligible NDMM

Opinion
Video

Panelists discuss how the evolving treatment landscape for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM) is being shaped by emerging data on optimal treatment sequencing strategies, both in frontline settings and subsequent lines of therapy.

Video content above is prompted by the following:

  1. As treatments continue to evolve, how do you see the future treatment landscape changing for patients with transplant-eligible NDMM?
    1. How do the data inform your consideration of treatment sequencing beyond the front line?
Recent Videos
7 experts are featured in this series.
7 experts are featured in this series.
5 experts are featured in this series
3 panelists
5 panelists
3 experts are featured in this series
3 panelists
Related Content
Data from a phase 1 trial may support additional clinical studies of CT0596 in relapsed/refractory multiple myeloma.

Novel Anti-BCMA Agent Shows Preliminary Responses in R/R Multiple Myeloma

Russ Conroy
December 20th 2025
Article

Data from a phase 1 trial may support additional clinical studies of CT0596 in relapsed/refractory multiple myeloma.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Based on phase 1 data, GC012F/AZD0120 may broaden therapeutic options for patients with newly diagnosed multiple myeloma.

All Respond to BCMA/CD19 CAR T-Cell Therapy in NDMM Trials

Chris Ryan
December 19th 2025
Article

Based on phase 1 data, GC012F/AZD0120 may broaden therapeutic options for patients with newly diagnosed multiple myeloma.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Alan Pliskin and Mary Kay Yamamoto discuss their journey through multiple myeloma treatment, emphasizing the importance of knowledge, positivity, and quality of life.

How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?

Tim Cortese
December 14th 2025
Article

Alan Pliskin and Mary Kay Yamamoto discuss their journey through multiple myeloma treatment, emphasizing the importance of knowledge, positivity, and quality of life.

The median OS among patients with triple-class–exposed relapsed/refractory multiple myeloma with or without EMD was 12.6 months vs 36.4 months.

EMD Associated With Poorer Outcomes in Previously Treated R/R Multiple Myeloma

Roman Fabbricatore
December 13th 2025
Article

The median OS among patients with triple-class–exposed relapsed/refractory multiple myeloma with or without EMD was 12.6 months vs 36.4 months.